Quince Therapeutics discloses departure of President Charles Ryan
The company reported the leadership change in an 8-K with an event date of August 23, 2026, and a signature date of August 27, 2026.
Quince Therapeutics, Inc. reported in a Form 8-K with a date of report of August 23, 2026 that on August 23, 2026, Quince Therapeutics, Inc. and Charles Ryan, the Company's President, determined that Mr. Ryan's last day of employment will be September 8, 2026.1
According to the filing, in connection with the conclusion of his service as the Company's President, Mr. Ryan will be eligible for certain severance benefits under the terms of his Executive Change in Control and Severance Agreement, dated September 1, 2023, by and between Mr. Ryan and the Company, as described under "Executive Compensation, Potential Payments Upon Termination or Change of Control" in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on August 25, 2026.
The 8-K was signed on behalf of the company by Chief Executive Officer Dirk Thye, with the signature dated August 27, 2026.
Quince Therapeutics is registered under the trading symbol QNCX on the Nasdaq Global Select Market, according to the filing. The company's principal executive offices are located at 611 Gateway Boulevard, Suite 273, South San Francisco, California, per the filing's cover page.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.